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Background: Asian patients undergoing kidney transplantation (KT) generally have better renal allograft survival
and a lower burden of cardiovascular disease than those of other racial groups. The KNOW-KT aims to explore
allograft survival rate, cardiovascular events, and metabolic profiles and to elucidate the risk factors in Korean KT
patients.
Methods: KNOW-KT is a multicenter, observational cohort study encompassing 8 transplant centers in the Republic
of Korea. KNOW-KT will enroll 1,000 KT recipients between 2012 and 2015 and follow them up to 9 years. At the
time of KT and at pre-specified intervals, clinical information, laboratory test results, and functional and imaging
studies on cardiovascular disease and metabolic complications will be recorded. Comorbid status will be assessed
by the age-adjusted Charlson co-morbidity index. Medication adherence and information on quality of life (QoL) will
be monitored periodically. The QoL will be assessed by the Kidney Disease Quality of Life Short Form. Donors will
include both living donors and deceased donors whose status will be assessed by the Kidney Donor Risk Index. Pri-
mary endpoints include graft loss and patient mortality. Secondary endpoints include renal functional deterioration
(a decrease in eGFR to <30 mL/min/1.73 m2), acute rejection, cardiovascular event, albuminuria, new-onset diabetes
after transplant, and QoL. Data on other adverse outcomes including episodes of infection, malignancy, recurrence
of original renal disease, fracture, and hospitalization will also be collected. A bio-bank has been established for the
acquisition of DNA, RNA, and protein from serum and urine samples of recipients at regular intervals. Bio-samples
from donors will also be collected at the time of KT. KNOW-KT was registered in an international clinical trial registry
(NCT02042963 at http://www.clinicaltrials.gov) on January 20th, 2014.
Conclusion: The KNOW-KT, the first large-scale cohort study in Asian KT patients, is expected to represent the Asian
KT population and provide information on their natural course, complications, and risk factors for complications.
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Table 1 Inclusion and exclusion criteria of the KNOW-KT
Inclusion criteria Exclusion criteria
Kidney transplant recipients
and donors
Simultaneous multiple organ
transplantation
Age > 18, both donors and
recipients
En-bloc KT recipients
Agreed to participate and
sign the consent form
Comorbidities of liver cirrhosis or
interstitial lung disease at the time of
transplant
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The number of end stage renal disease (ESRD) patients
has been increasing worldwide. In ESRD patients, the
benefits in relation to survival and quality of life are
greater with kidney transplantation (KT) than with dialy-
sis. As the acute rejection rate is currently decreasing,
long-term complications have become an important
issue in KT patients. However, the incidence and pat-
terns of complications in Asian KT patients may be dif-
ferent from those in Western countries. For example, a
prospective cohort study for Chinese general population
[1] and a retrospective study for Korean transplant pa-
tients [2] reported a lower incidence of ischemic heart
disease than that reported in Western countries. There-
fore, it is necessary to analyze outcomes and complica-
tions in KT patients in Asian countries.
The number of KTs has been increasing in Korea, and
the incidence and prevalence are 33.5 and 272.3 per mil-
lion people, respectively [3]. Outcomes of KT in Korea
are very good in both graft and patient survival rates.
Furthermore, deceased donor (DD) KT program is the
most active in Korea among Asian countries with the es-
tablishment of donor action programs, and the propor-
tion of DDKTs reached approximately 43.1% in 2012. In
this sense, a systemic analysis of Korean transplant data
could be valuable as representative data of the Asian
population.
After transplantation, renal function tends to de-
crease with time. More than 60% of KT patients have
an estimated glomerular filtration rate (eGFR) less than
60 mL/min/1.73 m2 at 1 year after transplantation, and a
mild degree of proteinuria or hematuria is commonly seen
in KT patients [4]. Therefore, more than 90% of KT pa-
tients are indeed chronic kidney disease patients [5]. KT
patients have various complications that are derived from
chronic immunosuppression or chronic kidney disease
status. Cardiovascular events, malignancy, infection, and
chronic rejection are the main cause of mortality or allo-
graft failure in KT patients, and the patients also suffer
from metabolic and psychosocial complications and
mineral bone disorder. Analysis of the incidence and
risk factors for these complications is necessary to con-
trol complications and improve transplant outcomes.
Several prospective, observational cohort studies have
been performed in the Europe and North America [6-9];
however, well-designed studies in other regions are lack-
ing. The KoreaN cohort study for Outcome in patients
With KT: A 9-year Longitudinal cohort study of the Ko-
rean adult KT patients (KNOW-KT), funded by Korea
Center for Disease Control and Prevention (KCDC), was
launched in 2012 by a group of nephrologists, surgeons,
epidemiologists, and biostatisticians in Korea. We aimed
to establish an adult KT cohort; to investigate the renal allo-
graft outcomes, mortality, and complications; to exploretraditional or nontraditional risk factors for morbidity and
mortality; and to establish bio-bank to integrate clinical and
biological information. Here, we report the design and
methodology of the KNOW-KT.
Methods
Organization
The KNOW-KT is being conducted in eight university-
affiliated Korean transplant centers (four in Seoul City,
one in Incheon city, one in Chonbuk Province, and two
in Kyoungbuk Province), and involves a team of epide-
miologic experts and a bio-bank in the KCDC. Epidemi-
ologists and biostatisticians in the Medical Research
Collaborating Center of Seoul National University Hospital
(MRCC) are responsible for data management and statis-
tical analysis. The KNOW-KT runs the steering commit-
tee to guide the study. The study is supervised by the
Chronic Kidney Disease Advisory Committee composed
by the members of the KCDC and the Korean Society of
Nephrology.
Study objectives
The primary objective of the present study is to delin-
eate the predictors of graft failure, patient mortality, and
cardiovascular and metabolic complications after KT.
The secondary objective is to describe various aspects of
other complications based on prospectively collected
data.
Study design and study population
This is a prospective, observational cohort study. Total
enrollment population will be 1,000 adult KT recipients
and their corresponding donors. Study recruitment will
be performed over 4 years from 2012 to 2015. The study
population will be followed up for 9 years or until their
death, graft failure, or drop out. Study inclusion and ex-
clusion criteria are shown in Table 1. Participating sub-
jects will visit each center according to the follow-up
schedule. At each visit, the subjects will undergo sched-
uled tests and be reviewed by the investigators for recent
medical history and event occurrence. Efforts will be made
in order to prevent drop-outs, i.e., providing free medical
tests, frequent telephone calls and dietary education.
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Baseline data will be collected during the pre-transplant
screening period, which include socio-demographic infor-
mation (age, sex, smoking history, history of alcohol drink-
ing), information on quality of life (QoL), socio-economic
status, educational level, physical activity, health behaviors,
and health care facility utilization. Comorbid status will be
assessed by the age-adjusted Charlson co-morbidity index
[10]. The QoL will be assessed by the Kidney Disease
Quality of Life Short Form (KDQoL-SF) [11]. The
KDQoL-SF consists of generic core (physical compo-
nent summary and mental component summary) and
kidney disease-targeted domains (symptoms/problems,
burden of kidney disease, and effects of kidney dis-
ease). Generic core represents the physical and mental
aspects of QoL, and kidney disease-targeted domains
focus on disease-related concerns. At the time of KT,
the following clinical parameters will be collected; (1)
general information about transplant (date of trans-
plantation, number of transplant experience, donor-
recipient relationship and desensitization) (2) recipient
information (date of birth, sex, cause of ESRD, comor-
bidities such as diabetes mellitus and hypertension,
history of malignancy, history of cardiovascular dis-
eases, and medications including immunosuppressant)
(3) donor information (date of birth, sex, body weight,
height, comorbidities such as hypertension, history of
malignancy). Donors include both living donors and
DDs. DDs include brain death donors of standard and
expanded criteria, and donation after cardiac death.
The quality of DD kidneys will be assessed by the Kid-
ney Donor Risk Index [12]. Physical examination in-
cluding anthropometric measurements (height, weight,
waist-to-hip ratios) and measurements of the resting
office blood pressure and pulse pressure will be con-
ducted. Laboratory tests include serum levels of calcium,
phosphorus, parathyroid hormone, total cholesterol, high-
density lipoprotein cholesterol, triglycerides, low-density
lipoprotein cholesterol (calculated), hemoglobin, glycated
hemoglobin, and C-reactive protein. Immunologic evalu-
ation includes human leukocyte antigen (HLA) typing,
performing HLA crossmatch (complement-dependent
cytotoxicity-based method and flow cytometry-based
method), and measuring panel reactive antibody levels.
Pre-transplant echocardiography, measurement of pulse-
wave velocity and ankle brachial index, and coronary cal-
cium computed tomography will be performed as cardiac
evaluations.
Complication events will be collected annually as an
event-based report including the date in which compli-
cation occurred. Follow-up examinations are scheduled
once a year. Evaluation schedule of the KNOW-KT at
each visit (Table 2) summarized details regarding the
schedules for study visits, tests, and questionnaires.Immunosuppressive medications at discharge will be re-
corded as a baseline, and then they will be recorded an-
nually. Medication adherence will be monitored annually
using Health Questionnaires.
All the reported data will be collected in a predefined
case report format and subsequently entered into a web-
based electronic data-warehouse. The electronic data input
and management system for the KNOW-KT was devel-
oped by the data management division in the MRCC.
Study outcomes
Primary endpoints include graft loss and patient mortal-
ity. Graft loss is defined as requiring maintenance dialy-
sis for more than 3 months or re-transplantation. The
cause of graft loss will be pursued. Patient mortality will
be classified into cardiac, noncardiac, and unknown
death. Subjects who drop out from the study will be
traced for this information with the help of National
Health Insurance Cooperation and Korea Statistical In-
formation Service.
Secondary endpoints include renal functional deterior-
ation, acute rejection, cardiovascular event, albuminuria,
new-onset diabetes after transplant, and QoL. Renal func-
tional deterioration is defined as a decrease in eGFR to
less than 30 mL/min/1.73 m2 after transplantation. Serum
creatinine will be measured by an isotope-dilution mass
spectrometry (IDMS)-traceable method. Estimations for
defining renal deterioration will be based on both the
four-variable Modification of Diet in Renal Disease for-
mula [13], and Chronic Kidney Disease Epidemiology
Collaboration creatinine equation [14]. Cardiovascular
events include myocardial infarction, coronary revascular-
ization, stroke and new onset or aggravation of congestive
heart failure.
Data on other adverse outcomes including episodes of
infection, malignancy, recurrence of original renal disease,
fracture, chronic liver disease, and hospitalization will also
be collected.
Reference populations for the evaluation of chronic
complications
To compare the risk of developing chronic medical com-
plications, we plan to use two reference populations.
One consists of approximately 3,000 CKD patients who
are enrolled in the KoreaN cohort study for Outcome in
patients With Chronic Kidney Disease (KNOW-CKD),
and the other is the general Korean population compiled
from the compulsory national health insurance program
without any claims under the diagnosis of CKD. Data
from the KNOW-CKD will be used for a pooled analysis
to provide the incidence rate ratios adjusting for various
risk factors. For the comparison between the general
population and the KNOW-KT, standardized incidence
rates will be presented.
Table 2 Evaluation schedule of the KNOW-KT at each visit
Visit*
Parameter Screening Baseline 1 2 3 4 5 6 7 8 9
Informed consent O
Medical History O
Eligibility confirmation O
Recent events O O O O O O O O O
Medications O O O O O O O O O O
Health Questionnaires O O O O O O O O O O
KDQOL questionnaires O O O O O
Blood pressure O O O O O O O O O O
Anthropometry O O O O O O O O O O
CBC, chemistry O O O O O O O O O O
IDMS-serum Cr, eGFR O O O O O O O O O O
Cystatin C O O O O O O O O O O
HbA1c (diabetic subjects) O O O O O O O O O O
Lipid, CRP, iron profile O O O O O O O O O O
Intact PTH, vitamin D1 O O O O O O O O O O
Urinalysis O O O O O O O O O O
Urine protein/creatinine O O O O O O O O O O
EKG, chest X ray O O O O O O O O O O
Serum BK real time PCR O O
PRA I & II O O O
HLA crossmatch O
HLA typing O
Viral serology2 O
LS spine Lateral X-ray for vascular calcification O O O O O O O O O O
Pulse wave velocity,Ankle-brachial index O O O
Echocardiography O O O
MDCT for coronarycalcium score O O
Bone mineral density O O O
DNA sample* O
Serum/urine sample O O O O
RNA sample O O O
CBC, complete blood count; CMV, cytomegalovirus; CRP, C-reactive protein; HLA, human leukocyte antigen; IDMS-serum cr, serum creatinine measurement using
IDMS-traceable method; KDQOL, Kidney Disease Quality of Life; MDCT, multidetector computed tomography; PRA, panel reactive antibody; PTH, parathyroid
hormone. 125-hydroxy- and 1,25-dihyroxy-vitamin D. 2HBsAg, anti-HBs, anti-HCV, and anti-CMV IgG.
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As baseline DNA samples, 4 mL of the whole blood
from recipients, collected in ethylenediaminetetraacetic
acid tube will be used. Another 10 mL of whole blood
will be collected in serum separation tube and centri-
fuged within 1 hour for serum sample stock. Ten mL of
morning first-voided urine samples will be taken for
urine sample stock and urine sediments will also be pre-
pared by centrifugation. Aliquots of the serum and urine
samples will be stored in a deep freezer (−70 °C). Serum
and urine samples will be collected at baseline and year1, 3, and 5 after enrollment. For RNA extraction and
storing, 10 mL of whole blood will be collected in PAX-
geneW tubes (Qiagen Inc., Valencia, CA, USA) at year 1, 3,
and 5 visits. DNA samples from donors will be collected
in the same manner as in the recipients. Sampling, deliv-
ery, and storage of samples will be under strict monitoring
throughout the study period.
Ethical considerations
The study is conducted under the Declaration of Helsinki.
The regional ethical committee and Institutional Review
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protocol. Informed consent in written form is essential
to recruit study population, for both donor and recipi-
ents. It was also registered in an international clinical trial
registry (NCT02042963 at http://www.clinicaltrials.gov)
on January 20th, 2014.
Statistical considerations
Descriptive analysis will be performed for baseline data.
Normally distributed continuous variables will be pre-
sented as mean ± standard deviation. For nonparametric
continuous variables, median with interquartile ranges
will be used as the summarizing values. Categorical data
will be presented with numbers and proportions. Com-
parison of continuous variables will be conducted with
t-test or Wilcoxon rank-sum test, and categorical vari-
ables will be compared using chi-squared test or Fisher’s
exact test as appropriate.
Survival time of grafts or patients, time to cardiovas-
cular outcomes (myocardial infarction, ischemic stroke,
etc.) and renal outcomes (graft loss, renal functional de-
terioration, acute rejection, etc.) will be estimated using
Kaplan-Meier curves. Cox proportional hazard models
will be used for comparison for the incidence of those
outcomes among groups with and without each risk fac-
tor. However, patient death is a competing cause of renal
outcomes or cardiovascular outcomes. Therefore, we will
adopt competing risk models in evaluating the contribu-
tions of risk factors for those outcomes. For time-varying
covariates that break the proportional hazard assumption,
an extended Cox model to compare the risk of outcomes
will be used.
Since more than 60% of KT patients have CKD at
1 year after transplantation [4], and CKD patients often
have a non-linear eGFR decline or a prolonged period of
non-progression [15], the pattern of renal functional de-
terioration will be explored using the Bayesian smooth-
ing technique [16]. We will compare eGFR decline in
serial measurements using a mixed linear model consid-
ering the longitudinal nature of our data. The general-
ized estimating equation will be used for estimating the
slope of the eGFR in the area of steady and linear eGFR
decline.
We will enroll 1,000 KT patients from participating
centers. We assumed that the incidence of cardiovascu-
lar complications at 5 years would be 22% [17]. With
that assumption, the sample size will detect a relative
risk of 1.46 or more by a risk factor with a prevalence of
50% at 5% alpha and 20% beta in an analysis using Cox
regression model. Assuming the same significance level
and statistical power, for a risk factor with prevalence of
12%, the sample size would detect a relative risk of 2.00
or higher as significant from same statistical model.
Analysis will be performed by using SAS 9.3 (SASInstitute, Cary, NC, USA). Statistical analysis will be 2-
sided, and p-value < 0.05 will be considered statistically
significant.
Study status
The KNOW-KT has enrolled 535 patients until now,
and plans to enroll a total of 1,000 patients by 2015.
Discussion
Although modern immunologic assessments and potent
immunosuppression markedly decreased the acute rejec-
tion rate in KT, it fails to suppress chronic rejection due
to immunologic and non-immunologic factors; this has
becomes a major obstacle for long-term graft survival.
Furthermore, as both graft and patient survival improve,
KT patients, who are often in the early stages of CKD,
become exposed to chronic immunosuppression. There-
fore, KT patients can develop many medical complications
such as cardiovascular events, metabolic complications,
infection, malignancy, and mineral bone disorders as well
as chronic rejection. Indeed, chronic medical complica-
tions have become a major cause of morbidity and mortal-
ity in KT patients.
Antibody-mediated injury is an important cause of
immunologic injury in chronic rejection or chronic
allograft nephropathy. Because noncompliance is one
of main causes of antibody formation, compliance
monitoring together with antibody monitoring is in-
cluded in our prospective study. Hypertension, hyper-
lipidemia, and diabetes, so called non-immunologic
risk factors for chronic allograft nephropathy, are com-
mon after KT and are reported to induce chronic damage
to allografts.
The nonimmunologic risk factors for chronic allograft
nephropathy are among traditional risk factors for car-
diovascular disease. Cardiovascular events have been re-
ported to be the most common cause of death in KT
patients in Western countries. However, many studies
show that racial/ethnic disparities exist in mortality and
cardiovascular outcome among CKD patients [18-21].
Transplant outcomes seem to differ according to racial
differences [22,23]. Asian KT patients generally have bet-
ter renal allograft survival and a lower burden of cardio-
vascular disease than other racial groups. The KNOW-KT,
the first large-scale cohort study in Asian KT patients,
aims to explore allograft survival rate, cardiovascular
events, and metabolic profiles and to investigate the risk
factors in Asian or Korean KT patients.
Risk for malignancy is higher in CKD patients than in
the general population [24]. Moreover, the risk for ma-
lignancy is higher in KT patients than in CKD patients
due to chronic immunosuppression. The relative preva-
lence of common malignancy differs according to region.
For example, gastric and hepatic cancers are the most
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as common in Western countries. Therefore, malignancy
patterns in KT patients could differ between Asian and
Western countries. Infectious complications are also one
of the main complications after transplantation. There
may be differences in immunosuppressive protocols or
prophylaxis policy due to differences in health insurance
coverage or disease prevalence. These potential differ-
ences could result in different patterns of infection in
Korean KT patients. Analysis of local infection profiles
can help in redirecting prophylactic policy for KT patients
in a specific country.
The KNOW-KT will evaluate the complication profiles
of mineral-bone disorders across various renal functions.
The KNOW-KT will also evaluate the socio-economic
burden and impact on the quality of life. Comparison of
the KNOW-KT with other large-scale KT cohorts through
international collaboration may provide a platform for
future research.
Various biomarkers from the serum and urine samples
will be explored for the risk prediction of adverse conse-
quences. Genetic and epigenetic factors will be sought.
Interaction between donor factors and recipient factors
is a unique feature in transplant cohorts and cannot be
seen in conventional CKD cohorts. Especially, analysis of
bio-samples from both living donors and DDs together
with recipient bio-samples could be one of the strengths
of the present cohort study.
The Collaborative Transplant Study (CTS) based in
Europe [25], the Scientific Registry of Transplant Recipi-
ents (SRTR) in USA [26], and the Australia and New
Zealand Dialysis and Transplant (ANZDATA) registry
are large-scale registries [27]. All these large cohorts
have strengths related to the large sample size and the
fact that they are representative as nationwide database,
whereas they also have limitations inherent to as registry
data, such as simplicity of the outcome data and the het-
erogeneity of clinical follow-up data. They usually do
not collect bio-samples that are matched with clinical
data. However, the KNOW-KT clearly defined outcomes
and carefully monitors study processes in order to meet
predefined protocols and establish a bio-bank together
with clinical data.
There are a few limitations in the KNOW-KT. First,
the KNOW-KT will enroll a relatively small number of
patients compared with the larger-scale registry database
or the cohort studies in Western countries. Therefore,
we should expand out cohort later in order to confirm
some of the findings. Second, all routine laboratory and
sampling procedures are processed in individual local
transplant centers, although transport and storage of
biospecimens are managed by a central laboratory. How-
ever, standards, laboratory methods, measurement units,
and detection limits are generally consistent among theselocal laboratories; therefore, the discrepancies among pro-
cedures at individual laboratories will only have limited ef-
fects on the quality of collected data, if any. Third, we do
not mandatorily collect kidney biopsy samples; instead, it
depends on the policy of individual center. Nevertheless,
the KNOW-KT is the first large-scale KT cohort study in
Asian KT patients. Future larger-scale studies could con-
firm the major findings of this study.
As the first large-scale Asian KT cohort study to be
performed longitudinally for up to 9 years, the KNOW-
KT will help clarify the natural course, complication
profiles, and the risk factors of the Asian KT population.
Analyzing this cohort and comparing with other cohort
studies in Western countries will provide information
about the impact of race on transplant outcomes and a
comprehensive insight into KT.
Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
JY, JL, JCJ, and CA participated in the design and coordination of the study.
JL and Kyoungha Seo in the KNOW-KT Study Group are in charge of biostatistical
analysis. KHH, JBP, JHC, SL, HR, SYH, YHK, and BJP reviewed the study protocol. JY,
KHH, JBP, JHC, SL, HR, SYH, YHK, BJP, DJH, JCJ, SBP, WC, SKP, CDK, SJK, YSK, and CA
were involved in patient enrollment, and data collection. JY, JL, and JCJ drafted
the manuscript. All of the authors read, revised, and approved the final
manuscript.
Authors’ information
The KNOW-KT Study Group includes the following researchers:
Clinical centers
Seoul National University, Seoul National University Hospital
Curie Ahn, M.D. (PI)
Jaeseok Yang, M.D.
Jong Cheol Jeong, M.D.
Yonsei University Health System, Severance Hospital
Yu Seun Kim, M.D.
Myung Soo Kim, M.D.
Kyu Ha Huh, M.D.
Sungkyunkwan University, Seoul Samsung Medical Center
Sung Joo Kim, M.D.
Jae Berm Park, M.D.
Kyungpook National University Hospital
Chan-Duck Kim, M.D.
Jang-Hee Cho, M.D.
Chonbuk National University Hospital
Sung Kwang Park, M.D.
Sik Lee, M.D.
Gachon University, Gil Hospital
Wookyung Chung M.D.
Han Ro, M.D.
Keimyung University, Dongsan Medical Center
Sung-Bae Park, M.D.
Seung-Yeup Han, M.D.
Eunah Hwang, M.D.
Wooyeong Park, M.D.
Ulsan University, Seoul Asan Medical Center
Duck Jong Han, M.D.
Young Hoon Kim, M.D.
Epidemiology and Biostatistics
Department of Preventive Medicine, Seoul National University College of Medicine
Byung-Joo Park, M.D.
Medical Research Collaborating Center, Seoul National University Hospital
and Seoul National University College of Medicine
Joongyup Lee, M.D.
Yang et al. BMC Nephrology 2014, 15:77 Page 7 of 7
http://www.biomedcentral.com/1471-2369/15/77Kyoungha Seo, M.S.
Coordinating Center
Medical Research Collaborating Center, Seoul National University Hospital
and Seoul National University College of Medicine
Joongyup Lee, M.D.
Heejung Ahn, R.N.
Seong-eun Kim, R.N.
Central Laboratory
Donghee Seo, M.D., Lab Genomics, Korea
Dae Yeon Cho, Ph.D., Lab Genomics, Korea
Biobank
Korea Biobank, Korea Centers for Disease Control and Prevention, Osong, Korea
Korea Centers for Disease Control and Prevention
Dukhyoung Lee, M.D.
Hyekyung Park, M.D. (Project Officer)
Eunkyeong Jung, M.D.
Suyeon Jeong
Eunmi Ahn
Sil-Hae SungAcknowledgements
We thank all patients who participate in the KNOW-KT, and all the colleagues
who contribute to the operation of the study. This research was supported
by a fund (2013E3301601) from Korea Centers for Disease Control and
Prevention after peer-review by Korea Centers for Disease Control and
Prevention.
Author details
1Transplantation Center, Seoul National University Hospital, Seoul, Republic of
Korea. 2Medical Research Collaborating Center, Seoul National University
Hospital, Seoul, Republic of Korea. 3Department of Transplantation Surgery,
Severance Hospital, Yonsei University Health System, Seoul, Republic of
Korea. 4Department of Surgery, Sungkyunkwan University, Seoul Samsung
Medical Center, Seoul, Republic of Korea. 5Department of Internal Medicine,
Kyungpook National University Hospital, Seoul, Republic of Korea.
6Department of Internal Medicine, Chonbuk National University Hospital,
Seoul, Republic of Korea. 7Department of Internal Medicine, Gachon
University, Gil Hospital, Seoul, Republic of Korea. 8Department of Internal
Medicine, Keimyung University, Dongsan Medical Center, Seoul, Republic of
Korea. 9Department of Surgery, Ulsan University, Seoul Asan Medical Center,
Seoul, Republic of Korea. 10Department of Preventive Medicine, Seoul
National University College of Medicine, Seoul, Republic of Korea.
11Department of Internal Medicine, Seoul National University College of
Medicine, Seoul, Republic of Korea.
Received: 2 April 2014 Accepted: 16 April 2014
Published: 9 May 2014References
1. Liu J, Hong Y, D'Agostino RB Sr, Wu Z, Wang W, Sun J, Wilson PW, Kannel
WB, Zhao D: Predictive value for the Chinese population of the
Framingham CHD risk assessment tool compared with the Chinese
Multi-Provincial Cohort Study. JAMA 2004, 291(21):2591–2599.
2. Jeong JC, Ro H, Hwang YH, Lee HK, Ha J, Ahn C, Yang J: Cardiovascular diseases
after kidney transplantation in Korea. J Kor Med Sci 2010, 25(11):1589–1594.
3. Jin DC, Han JS: Renal replacment therpay in Korea, 2012. Kidney Res Clin
Pract 2014, 33(1):9–18.
4. Samaan F, Requiao-Moura LR, Pinheiro HS, Ozaki KS, Saraiva Camara NO,
Pacheco-Silva A: Prevalence and progression of chronic kidney disease
after renal transplantation. Transplant Proc 2011, 43(7):2587–2591.
5. Fernandez-Fresnedo G, de Francisco A, Ruiz JC, Cotorruelo JG, Alamillo CG,
Valero R, Castaneda O, Zalduendo B, Izquierdo MJ, Arias M: Relevance of
chronic kidney disease classification (K/DOQI) in renal transplant
patients. Transplant Proc 2006, 38(8):2402–2403.
6. Kasiske BL, Israni AK, Snyder JJ, Camarena A, Investigators C: Design considerations
and feasibility for a clinical trial to examine coronary screening before
kidney transplantation (COST). Am J Kid Dis 2011, 57(6):908–916.
7. Matas AJ, Leduc R, Rush D, Cecka JM, Connett J, Fieberg A, Halloran P,
Hunsicker L, Cosio F, Grande J, Mannon R, Gourishankar S, Gaston R, Kasiske B:
Histopathologic clusters differentiate subgroups within the nonspecificdiagnoses of CAN or CR: preliminary data from the DeKAF study. Am J
Transplant 2010, 10(2):315–323.
8. Shao P, Tang L, Li P, Xu Y, Qin C, Cao Q, Ju X, Meng X, Lv Q, Li J, Zhang W,
Yin C: Application of a vasculature model and standardization of the
renal hilar approach in laparoscopic partial nephrectomy for precise
segmental artery clamping. Eur Urol 2013, 63(6):1072–1081.
9. Georg Y, Schwein A, Lejay A, Tartaglia E, Girsowicz E, Kretz JG, Thaveau F,
Chakfe N: Practical experience with the TAG and conformable TAG devices:
lessons learned in about 100 cases. J Cardiovasc Surg 2013, 54(5):605–615.
10. Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined
comorbidity index. J Clin Epidemiol 1994, 47(11):1245–1251.
11. Molnar-Varga M, Molnar MZ, Szeifert L, Kovacs AZ, Kelemen A, Becze A,
Laszlo G, Szentkiralyi A, Czira ME, Mucsi I, Novak M: Health-related quality
of life and clinical outcomes in kidney transplant recipients. Am J Kid Dis
2011, 58(3):444–452.
12. Han M, Jeong JC, Koo TY, Jeon HJ, Kwon HY, Kim YJ, Ryu HJ, Ahn C, Yang J:
Kidney donor risk index is a good prognostic tool for graft outcomes in
deceased donor kidney transplantation with short, cold ischemic time.
Clin Transpl 2014, 28(3):337–344.
13. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW,
Van Lente F: Using standardized serum creatinine values in the modification
of diet in renal disease study equation for estimating glomerular filtration
rate. Ann Intern Med 2006, 145(4):247–254.
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI,
Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney
Disease Epidemiology Collaboration): A new equation to estimate glomerular
filtration rate. Ann Intern Med 2009, 150(9):604–612.
15. Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X,
Wright JT Jr, Greene TH: Longitudinal progression trajectory of GFR
among patients with CKD. Am J Kid Dis 2012, 59(4):504–512.
16. Crainiceanu CM, Ruppert D, Wand MP: Bayesian analysis for penalized
spline regression using WinBUGS. J Stat Softw 2005, 14(14):1–24.
17. Valdes-Canedo F, Pita-Fernandez S, Seijo-Bestilleiro R, Pertega-Diaz S,
Alonso-Hernandez A, Cillero-Rego S, Fernandez-Rivera C, Oliver-Garcia J:
Incidence of cardiovascular events in renal transplant recipients and
clinical relevance of modifiable variables. Transplant Proc 2007,
39(7):2239–2241.
18. Mehrotra R, Kermah D, Fried L, Adler S, Norris K: Racial differences in
mortality among those with CKD. J Am Soc Nephrol 2008, 19(7):1403–1410.
19. Muntner P, Newsome B, Kramer H, Peralta CA, Kim Y, Jacobs DR Jr, Kiefe CI,
Lewis CE: Racial differences in the incidence of chronic kidney disease.
Clin J Am Soc Nephrol 2012, 7(1):101–107.
20. Mok CC: Racial difference in the prognosis of lupus nephritis. Nephrology
(Carlton) 2010, 15(4):480–481.
21. Jovanovich A, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL,
Smits G, Kendrick J: Racial differences in markers of mineral metabolism in
advanced chronic kidney disease. Clin J Am Soc Nephrol 2012, 7(4):640–647.
22. Fan PY, Ashby VB, Fuller DS, Boulware LE, Kao A, Norman SP, Randall HB,
Young C, Kalbfleisch JD, Leichtman AB: Access and outcomes among
minority transplant patients, 1999–2008, with a focus on determinants
of kidney graft survival. Am J Transplant 2010, 10(4 Pt 2):1090–1107.
23. Katznelson S, Gjertson DW, Cecka JM: The effect of race and ethnicity on
kidney allograft outcome. Clin Transpl 1995:379–394.
24. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney
transplantation in the United States. Am J Transplant 2004, 4(6):905–913.
25. Opelz G, Dohler B, Ruhenstroth A, Cinca S, Unterrainer C, Stricker L, Scherer S,
Gombos P, Susal C, Daniel V, Tran H: The collaborative transplant study
registry. Transplantat Rev 2013, 27(2):43–45.
26. Annual Data Report of the US Organ Procurement and Transplantation
Network (OPTN) and the Scientific Registry of Transplant Recipients
(SRTR). Introduction. Am J Ttransplant 2013, 13(Suppl 1):8–10.
27. Gray NA, Mahadevan K, Campbell VK, Noble EP, Anstey CM: Data quality of
the Australia and New Zealand Dialysis and Transplant Registry: a pilot
audit. Nephrology (Carlton) 2013, 18(10):665–670.
doi:10.1186/1471-2369-15-77
Cite this article as: Yang et al.: KNOW-KT (KoreaN cohort study for
outcome in patients with kidney transplantation: a 9-year longitudinal
cohort study): study rationale and methodology. BMC Nephrology
2014 15:77.
